PROGNOSTICATION IN CLL: PRESENT AND FUTURE
|
|
- Maryann Shelton
- 5 years ago
- Views:
Transcription
1 PROGNOSTICATION IN CLL: PRESENT AND FUTURE Gianluca Gaidano, M.D., Ph.D. Division of Hematology Department of Translational Medicine Amedeo Avogadro University of Eastern Piedmont Novara-Italy
2 CLL: Homogeneous phenotype but heterogeneous clinical course Highly stable Lymphocytes years Slowly progressive Lymphocytes Tx years Rapidly progressive Lymphocytes Tx Tx Tx Tx months
3 Pathogenesis of CLL Trasforming Lesion Microenvironment Interactions Secondary Lesion Predisposition Initiation Promotion/Accumulation Progression Chemorefractoriness Transformation Polygenic IRF4 IRF8 MYC Other del13q +12 Signaling pathways BCR NF-kB TLR CD38 VLA-4 integrins NOTCH CXCR4 TP53 NOTCH1 SF3B1 BIRC3 ATM MYC CDKN2A
4 CLL mutations Font size according to gene mutation prevalence 3601 genes mutated in CLL from the COSMIC v71 database 100 genes mutated in 2 or more CLL 4 genes recurrently mutated in >5% of CLL Fabbri, J Exp Med 2011; Puente, Nature 2011; Rossi, Blood 2011; Quesada, Nat Genet 2011; Wang, N Engl J Med 2011; Rossi, Blood 2012
5 Applications of genetic biomarkers in CLL Survival Treatment tailoring Prognosticator Factors that provide information on the likely outcome of CLL Predictor Factors that provide information on the likely benefit from a specific CLL treatment Italiano A, J Clin Oncol 2011
6 Prognosticators and predictors in CLL Prognosticators Predictors Richter transformation TP53 disruption NOTCH1 mutations Gene mutations IGHV mutation FISH karyotype CLL BCR pathway mutations
7 FISH karyotype: Pivotal evidence that genetics stratifies CLL survival 13q-Deletion Survival Trisomy 12 (N=325) Months Döhner H, et al. N Engl J Med. 2000
8 Prognosticators and predictors in CLL Prognosticators Predictors Richter transformation TP53 disruption NOTCH1 mutations Gene mutations IGHV mutation FISH karyotype CLL BCR pathway mutations
9 UK LRF CLL4: validation of the impact of NOTCH1 and SF3B1 mutations on OS 100 NOTCH1 100 SF3B1 Survival Probability Wild-type Survival Probability Wild-type Mutant Mutant Time from Randomization (mths) NOTCH1 Sur. (mths) 95% CI Events P-value Wild-type Mutant Time from Randomization (mths) SF3B1 Sur. (mths) 95% CI Events P-value Wild-type Mutant <0.001 Courtesy of D. Oscier and J. Strefford Oscier DG, et al. Blood 2013;121:
10 Integrating mutation and cytogenetics for CLL survival prognostication Survival Cumulative probability of OS (%) Matched general population Years from diagnosis N 10-year OS 10-year relative OS del13q 26% 69% 84% Normal/+12 40% 57% 70% NOTCH1 M/SF3B1 M/del11q 17% 37% 48% TP53 DIS/BIRC3 DIS 17% 29% 37% Rossi et al, Blood 2013
11 Impact of gene mutations on treatment free survival from diagnosis Binet A cases 100% % untreated 75% 50% 25% all negative, n=211 TP53abn, n=56 SF3B1, n=43 NOTCH1, n=55 del(11q), n=76 trisomy 12, n=83 del(13q), n=294 p< Median TTFT (years) del13q del11q 2.7 NOTCH1 M 3.3 SF3B1 M 3.1 TP53 DIS 2.9 0% Time (years) Baliakis et al, Leukemia 2014
12 Prognosticators and predictors in CLL Prognosticators Predictors Richter transformation TP53 disruption NOTCH1 mutations Gene mutations IGHV mutation FISH karyotype CLL BCR pathway mutations
13 NOTCH1 mutations predispose to the development of Richter syndrome MYC activation TP53 disruption Trasnformation Chemoresistance Rapid disease kinetics Driving forces Rossi, et al. Blood 2012 Villamor, et al. Leukemia 2013 NOTCH1 mutation CLL CDKN2A disruption DLBCL (Richter) NOTCH1 wt NOTCH1 NOTCH1 wt wt NOTCH1 wt NOTCH1 M NOTCH1 M p<.001 p<.001 NOTCH1 M NOTCH1 M Events Total 5-year Events risk Total 5-year risk 10-year risk 10-year risk NOTCH1 wt NOTCH1 18 wt 531 5% NOTCH1 5% wt NOTCH1 6% wt 6% NOTCH1 M NOTCH1 12 M 74 45% NOTCH1 45% M NOTCH1 41% M 41%
14 Risk of Richter transformation according to NOTCH1 status and stereotyped BCR at CLL diagnosis NOTCH1 wt & no IGHV4-39 NOTCH1 wt & IGHV4-39 NOTCH1 M & no IGHV4-39 NOTCH1 M & IGHV4-39 p<.001 p<.001 No. at Risk NOTCH1 wt & no IGHV NOTCH1 wt & IGHV NOTCH1 M & no IGHV NOTCH1 M & IGHV Events Total 5-year risk 95% CI NOTCH1 wt & no IGHV % NOTCH1 wt & IGHV NOTCH1 M & no IGHV % NOTCH1 M & IGHV % Rossi, et al. Br J Haematol 2012
15 Prognosticators and predictors in CLL Prognosticators Predictors Richter transformation TP53 disruption NOTCH1 mutations Gene mutations IGHV mutation FISH karyotype CLL BCR pathway mutations
16 TP53 abnormalities in CLL Missense Nonsense Frameshift NOTCH1 SF3B1 SF3B TP EX4 EX9 1 DNA BINDING 393 TP53 TP53 17p 17p 11q 11q q 13q IGHV-U Chr17 All IGHV U IGHV M normal 13q q- 17p- Frequency 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% N=1/63 (1.5%) MBL TP53 M del17p13 TP53 M/del17p13 N=13/268 (4.8%) Early stage CLL N=30/318 (9.4%) CLL requiring treatment N=44/99 (44.4%) F-refactory CLL N=25/38 (65.7%) Richter syndrome Caspase 9 cdc2 p21 cyclin B Cell cycle arrest Apoptosis BAX p21 cyclin B p53 P DNA damage p53 P P Dohner et al, New Engl J Med 2000 ; Rasi et al, Haematologica 2012; Zainuddin et al, Leuk Res 2011; Zenz et al J Clin Oncol 2010; Rossi et al Blood 2011, Stilgenbauer, Blood 2014
17 TP53 abnormalities in CLL FCR 17p- on FCR 17p-censored 11q-censored +12q-censored 13q-singlecensored No aberrationcensored FC and TP53 WT FC and TP53 mut FCR and TP53 WT FCR and TP53 mut PFS Months Months Hallek et al, ASH 2009 Stilgenbaueret al, ASH 2012 EHA-20: Ljungstrom S121; Tausch LB2070 (novel FCR prognosticators)
18 Allo-SCT in High-Risk CLL CLL3X: multicenter GCLLSG Genomic 100 unknown (18) aberrations 17p- (13) 11q- (26) other (21) 13q- (12) 50 Event-free Survival Months from SCT Dreger P, et al., Blood 2010; Dreger P, et al. Blood 2013
19 Clonal architecture of TP53 mutated CLL Scenario 1 Scenario 2 Scenario 3 TP53 mutation representation 80% Detectable by Sanger sequencing TP53 mutation representation 20% Barely detectable by Sanger sequencing TP53 mutation representation 1% Not detectable by Sanger sequencing
20 Small TP53 mutated subclones account for ~30% of all cases harboring TP53 defects Allele frequency corrected for tumor representation 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Sanger sequencing positive n=35 TP53 mutations Ultra deep-ngs 85 TP53 mutations in 46/309 (15%) CLL Sanger sequencing negative n=50 Median allele frequency: 2.1% (range: %) 6% TP53 mutations N=309 N=309 TP53 lesions* (N=18) 85% 7% 84% (N=263) (N=22) (N=259) 3% (N=10) 6% (N=18) 4% (N=13) 5% (N=15) subclonal M clonal M * TP53 mutations and 17p13 deletion clonal M+subclonal M wt subclonal M clonal M+subclonal M clonal M+del17p del17p subclonal M+del17p clonal M+subclonal M+del17p clonal M wt Rossi, Blood 2014
21 Small TP53 mutated subclones have the same unfavorable prognostic impact as clonal TP53 defects p from pairwise comparisons < < TP53 unmutated Solely subclonal TP53 M Clonal TP53 M ID9245 del17p p.g244d TP53 M (p.g244d) 100% 80% 66.0% 60% 40% 58.0% 20% 0.9% 0% -20% Allele frequency months No. at risk Diagnosis FCR CR Relapse Refractoriness Events Total 5-year OS 95% CI % % % % % % Rossi, Blood 2014
22 Small TP53 mutated subclones are selected by treatment because of their chemoresistance Diagnosis Chemotherapy Progression Chemotherapy Refractoriness TP53 unmutated Solely subclonal TP53 M Clonal TP53 M Small TP53 mutated subclone admixed with TP53 wild type clones Removal of TP53 wild type clones and selection of the TP53 mutated subclone Expansion of the TP53 mutated clone Poor outcome TP53 mutated CLL cell Rossi, Blood 2014
23 Guidelines recommendations on TP53 lesions in CLL NCI-IWCLL 2008 guidelines In the clinical practice, cytogenetics (FISH) del(17p) in the peripheral blood lymphocytes is desirable before treatment Repetition of FISH analyses seems justified before subsequent, second- and third-line treatment ERIC recommendations on TP53 mutation analysis TP53 mutations (exons 4-9) should be investigated immediately before treatment decision Outside clinical trials in patients requiring therapy who would be eligible to an allogeneic stem cell transplantation or other intensive therapies (e.g., FCR and BR) Previously treated patients with wild-type TP53 at the time of treatment, should be retested when further therapy is needed and results can be expected to influence choice of therapy British Committee for Standards in Haematology (BCSH) Patients should be screened for the presence of a TP53 abnormality prior to initial and subsequent treatment. Currently, TP53 loss should be assessed by FISH. Patients should also be screened for TP53 mutations when this assay becomes routinely avaliable (Grade B2). Hallek et al, Blood 2008 Oscier et al, Br J Haematol 2012 Pospisilova et al, Leukemia 2012
24 Prognosticators and predictors in CLL Prognosticators Predictors Richter transformation TP53 disruption NOTCH1 mutations Gene mutations IGHV mutation FISH karyotype CLL BCR pathway mutations
25 NOTCH1 mutations as predictive marker for no benefit from addition of anti-cd20 MoAb to chemotherapy GCLLSG CLL8 COMPLEMENT PFS Months Stilgenbauer et al, Blood 2014 Tausch et al, ASH 2013
26 Prognosticators and predictors in CLL Prognosticators Predictors Richter transformation TP53 disruption NOTCH1 mutations Gene mutations IGHV mutation FISH karyotype CLL BCR pathway mutations
27 IGHV mutated patients devoid of del17p and del11q gain the greatest benefit from FCR 1 del17p del_17p p<0.001 p < IGHV M IGHV UM/del11q del17p 2 del11q del_11q p=0.024 p = No 0 Yes 0 3 IGHV IGHV UM p p=0.011 = No Yes No 0 Yes 0 Progression free survival (%) Node 4 (n = 86) Node 5 (n = 233) Node 6 (n = 54) Node 7 (n = 30) p from pairwise comparisons < < Months Months Months Months Hazard of progression Hazard Rate IGHV M IGHV UM/del11q del17p IGHV UM and/or del11q Overall survival (%) Matched general population IGHV M IGHV UM/del11q del17p N Observed Expected 5-year relative 5-year OS (%) events events* OS* p* % % < % < Months Follow-up time (months) Months
28 Clonally related vs unrelated Richter syndrome 50/63 (80%) Clonally related RS V4-39 D6 J4 13/63 (20%) p=.018 p=.009 CLL V4-39 D6 J4 Clonally unrelated RS V4-34 D2-2 J3 Clonally unrelated Clonally related p=.017 Rossi et al, Blood 2011
29 Prognosticators and predictors in CLL Prognosticators Predictors Richter transformation TP53 disruption NOTCH1 mutations Gene mutations IGHV mutation FISH karyotype CLL BCR pathway mutations
30 Molecular mechanisms of resistance to ibrutinib BCR pathway Non-canonical NF-κB pathway BCR Ibrutinib CD79A CD79B BTK PLCG2 CLL TRAF3 TRAF2 BIRC3 CARD11 DLBCL MAP3K14 MALT1 BCL10 MCL IKBKB IKK BTK C481S mutation PLCG2 mutation Absent in ibrutinib naïve patients NF-kB activation Davis, Nature 2010 Woyach, NEJM 2014 Furman, NEJM 2014 Famà, Blood 2014 Rahal, Nat Med 2014
31 Mutations that are inert under chemotherapy may become dangerous under new agents and vice versa FCR kinase inhibitors KI resistant subclone FCR resitant subclone
32 IS THERE STILL A ROLE FOR IMMUNOPHENOTYPE IN CLL PROGNOSTICATION?
33 Pathogenesis of CLL Trasforming Lesion Microenvironment Interactions Secondary Lesion Predisposition Initiation Promotion/Accumulation Progression Chemorefractoriness Transformation Polygenic IRF4 IRF8 MYC Other del13q +12 Signaling pathways BCR NF-kB TLR CD38 VLA-4 integrins NOTCH CXCR4 TP53 NOTCH1 SF3B1 BIRC3 ATM MYC CDKN2A
34 CCR1 CCR5 CCL3 CCL4 Mo CLL CD49d TNF VCAM VCAM VCAM VCAM VCAM VCAM Pro-survival signals CRO AVIANO
35 CD49d is the strongest flow cytometry-based CLL prognosticator Bulian P et al. JCO 2014;32:
36 MRD as a POST-TREATMENT PROGNOSTICATOR for CLL
37 MRD-negativity may indicate deeper remission MRD-negative patients have fewer CLL cells after treatment Detectable Tumor Burden Baseline tumor burden 50% reduction Detection limit of standard staging techniques (~ 1 CLL cell in ) Clinical disease status SD PR 50% increase = PD Decrease 0 <50% = SD Decrease 50 <100% = PR Below this level = CR* Definition of MRD-negativity (< 1 CLL cell in 10,000) Deeper remission CR Cure? MRD+ CR MRD CR * May be PR for cytopenia or organ enlargement Hallek M, et al. Blood 2008; 111:
38 MRD can indicate depth of remission and predict relapse Remission Relative frequency of CLL cells MRDnegative Time < 10 4 = iwcll definition of MRD-negativity 2 Detection limit of cytology/ct scan 1 : Detection limits of flow cytometry and PCR techniques 3 : Still in remission and MRD-negative 1 Böttcher S, et al. Hematol Clin N Am 2013; 27: ; 2. Hallek M, et al. Blood 2008; 111: ; 3. Moreno C, et al. Best Pract Res Clin Haematol 2010; 23:
39 Clinical significance of MRD in CLL8 Patients in CLL8 were grouped by MRD level (blood) at initial response assessment Patients achieving MRD-negative status had the best outcome, regardless of treatment The extent of MRD reduction was important for outcome 1.0 PFS probability p < for all comparisons 10 2 (n = 45) Time (months) < 10 4 (negative) (n = 141) 10 4 to < 10 2 (n = 104) MRD by 4-color flow cytometry, validated against ASO-RQ-PCR Böttcher S, et al. J Clin Oncol 2012; 30:
40 PFS by MRD status in patients treated with G-Clb Goede V, et al. N Engl J Med 2014; 370: supl material
41 BUT: With some new drugs (eg: BCR inhibitors), MRD is of no/little use
42 Summary: clinical implications of mutations for the management of CLL TP53 assessment for treatment tailoring (chemoimmuno vs new inhibitors) Comprehensive genetic assessment to sort out patients who benefit most of FCR NOTCH1 mutations to identify patients at high risk of RS and resistance to anti-cd20 MoAb NGS as a new tool for highly sensitive detection of TP53 mutations Clonal relationship between CLL and DLBCL to identify prognostically favourable unrelated RS (de novo DLBCL) BTK and PLCG2 mutation testing to identify acquired resistance to KI
43 Summary: clinical implications of mutations for the management of CLL TP53 assessment for treatment tailoring (chemoimmuno vs new inhibitors) Comprehensive genetic assessment to sort out patients who benefit most of FCR NOTCH1 mutations to identify patients at high risk of RS and resistance to anti-cd20 MoAb NGS as a new tool for highly sensitive detection of TP53 mutations Clonal relationship between CLL and DLBCL to identify prognostically favourable unrelated RS (de novo DLBCL) BTK and PLCG2 mutation testing to identify acquired resistance to KI
44 NOTCH1, SF3B1, BIRC3, MYD88, & other.. Not ready for prime time because: Most evidence is based on retrospective cohorts Lack of robustness Dig into the across depth clinical of TP53 trials and avoid (eg: SF3B1 mutations predict OS in UK CLL4 but not in GCLLSG CLL8) random strolling across other biomarkers! Lack of uniform methodologies of detection across studies EHA-19 Lunch Debate: Stamatopoulos vs Gaidano Milan 2014
45 Suggestions for every day life Outside of clinical trials/research purposes, limit analysis of prognosticators/predictors to what is recommended by guidelines Do not modify (decrease/increase) the sensitivity threshold of the methodology recommended by guidelines Consider that the value of each prognosticator/predictor may be highly treatment-specific
46 University of Eastern Piedmont, Novara Davide Rossi Michaela Cerri Lorenzo De Paoli Silvia Rasi Alessio Bruscaggin Valeria Spina Lorenzo De Paoli Clara Deambrogi Sapienza University, Rome Anna Guarini Ilaria Del Giudice Francesca R Mauro Monica Messina Sabina Chiaretti Robin Foà Columbia University, New York Laura Pasqualucci Raul Rabadan Riccardo Dalla Favera
1. What to test. 2. When to test
Biomarkers: the triad of questions 1. What to test 2. When to test 3. Who to test Biomarkers: the triad of questions 1. What to test 2. When to test 3. Who to test Impact of CLL biological features on
More informationFATTORIPROGNOSTICINELLA LEUCEMIALINFATICACRONICA
Varese, 31-10-2014 FATTORIPROGNOSTICINELLA LEUCEMIALINFATICACRONICA Davide Rossi, M.D., Ph.D. Division of Hematology Department of Translational Medicine Amedeo Avogadro University of Eastern Piedmont
More informationImportance of minor TP53 mutated clones in the clinic
Importance of minor TP53 mutated clones in the clinic Davide Rossi, M.D., Ph.D. Hematology IOSI - Oncology Institute of Southern Switzerland IOR - Institute of Oncology Reserach Bellinzona - Switzerland
More informationLEUCEMIA LINFATICA CRONICA
LEUCEMIA LINFATICA CRONICA Gianluca Gaidano SCDU Ematologia Dipartimento di Medicina Traslazionale Università del Piemonte Orientale Novara Outline CLL biology and pathogenesis Prognostication and prediction
More informationChronic lymphocytic leukemia is eradication feasible and worthwhile?
Chronic lymphocytic leukemia is eradication feasible and worthwhile? Gianluca Gaidano, MD, PhD Division of Hematology Department of Clinical and Experimental Medicine Amedeo Avogardo University of Eastern
More informationREAL LIFE AMBULATORIALE E STUDI CLINICI RANDOMIZZATI NELLA PROGRAMMAZIONE TERAPEUTICA DELLA LEUCEMIA LINFATICA CRONICA.
REAL LIFE AMBULATORIALE E STUDI CLINICI RANDOMIZZATI NELLA PROGRAMMAZIONE TERAPEUTICA DELLA LEUCEMIA LINFATICA CRONICA Roberta Murru Struttura Complessa Ematologia e Centro Trapianti Presidio Ospedaliero
More informationChronic Lymphocytic Leukemia (CLL): Refresher Course for Hematologists Ekarat Rattarittamrong, MD
Chronic Lymphocytic Leukemia (CLL): Refresher Course for Hematologists Ekarat Rattarittamrong, MD Division of Hematology Department of Internal Medicine Faculty of Medicine Chiang-Mai University Outline
More informationChronic lymphocytic leukemia. E. Van Den Neste Cliniques UCL Saint-Luc, Brussels Post-ASH meeting January 2015
Chronic lymphocytic leukemia E. Van Den Neste Cliniques UCL Saint-Luc, Brussels Post-ASH meeting January 2015 Disclosures Travelling to ASH: Roche Consulting services: Janssen Questions in CLL: answers
More informationRichter syndrome: pathogenesis and management. Clemens Wendtner Professor of Medicine Chief Physician Klinikum Schwabing University of Munich
Richter syndrome: pathogenesis and management Clemens Wendtner Professor of Medicine Chief Physician Klinikum Schwabing University of Munich Conflict of Interest Disclosure I hereby declare the following
More informationPathology of the indolent B-cell lymphomas Elias Campo
Pathology of the indolent B-cell lymphomas Elias Campo Hospital Clinic, University of Barcelona Small B-cell lymphomas Antigen selection NAIVE -B LYMPHOCYTE MEMORY B-CELL MCL FL LPL MZL CLL Small cell
More informationCLL treatment algorithm and state of the art
CLL treatment algorithm and state of the art Davide Rossi, M.D., Ph.D. Hematology IOSI - Oncology Institute of Southern Switzerland IOR - Institute of Oncology Research Bellinzona - Switzerland CLL subgroups
More informationFCR and BR: When to use, how to use?
FCR and BR: When to use, how to use? Mitchell R. Smith, M.D., Ph.D. Director of Lymphoid Malignancy Program Taussig Cancer Institute Cleveland Clinic, Cleveland, OH DEBATE ISSUE 2013: Which is the optimal
More informationAdvances in CLL 2016
Advances in CLL 2016 The Geoffrey P. Herzig Memorial Symposium, Louisville, KY Kanti R. Rai, MD Northwell-Hofstra School of Medicine Long Island Jewish Medical Center New Hyde Park, NY Disclosures Member
More informationWe Can Cure Chronic Lymphocytic Leukemia with Current / Soon to be Approved Agents: CON ARGUMENT
We Can Cure Chronic Lymphocytic Leukemia with Current / Soon to be Approved Agents: CON ARGUMENT Danielle M. Brander, MD Duke University Division of Hematologic Malignancies & Cell Therapy CLL & Indolent
More informationLymphoma and microenvironment
Lymphoma and microenvironment Valter Gattei, MD Head Clinical and Experimental Oncology Unit IRCCS Aviano (PN) % viable cells CLL cells do need microenvironmental CLL and microenvironment... interactions
More informationCLL & SLL: Current Management & Treatment. Dr. Peter Anglin
CLL & SLL: Current Management & Treatment Dr. Peter Anglin Chronic Lymphocytic Leukemia Prolonged clinical course Chronic A particular type of blood cell B lymphocyte Lymphocytic Cancer of white blood
More informationManagement of 17p Deleted CLL Patients in the Era of Targeted Therapy
Management of 17p Deleted CLL Patients in the Era of Targeted Therapy Jennifer R Brown, MD PhD Director, CLL Center Dana-Farber Cancer Institute Associate Professor Harvard Medical School November 11,
More informationCLL Ireland Information Day Presentation
CLL Ireland Information Day Presentation 5 May 2018 Professor Patrick Thornton Consultant Haematologist, Senior Lecturer RCSI, and Clinical Director Hermitage Medical Clinic Laboratory Chronic Lymphocytic
More informationGenomic complexity and arrays in CLL. Gian Matteo Rigolin, MD, PhD St. Anna University Hospital Ferrara, Italy
Genomic complexity and arrays in CLL Gian Matteo Rigolin, MD, PhD St. Anna University Hospital Ferrara, Italy Clinical relevance of genomic complexity (GC) in CLL GC has been identified as a critical negative
More informationChronic lymphocytic Leukemia
Chronic lymphocytic Leukemia after IwCLL, ICML and EHA 2017 Ann Janssens, MD, PhD Hematology, UZ Leuven Brussels, 14 september 2017 Front line treatment CLL Active or progressive disease No active or progressive
More informationCLL what do I need to know as an Internist in Taimur Sher MD Associate Professor of Medicine Mayo Clinic
CLL what do I need to know as an Internist in 218 Taimur Sher MD Associate Professor of Medicine Mayo Clinic Case 1 7 y/o white male for yearly medical evaluation Doing well and healthy Past medical history
More informationQuando e se è possibile e u/le o0enere una remissione completa
Quando e se è possibile e u/le o0enere una remissione completa 1) Clinical heterogeneity Disease characteris:cs Pa:ent characteris:cs 2) Modern chemoimmunotherpy approaches 3) New mechanism- based treatment
More informationCLL & SLL: Current Management & Treatment. Dr. Isabelle Bence-Bruckler
CLL & SLL: Current Management & Treatment Dr. Isabelle Bence-Bruckler Chronic Lymphocytic Leukemia Prolonged clinical course Chronic A particular type of white blood cell B lymphocyte Lymphocytic Cancer
More informationTP53 mutational profile in CLL : A retrospective study of the FILO group.
TP53 mutational profile in CLL : A retrospective study of the FILO group. Fanny Baran-Marszak Hopital Avicenne Bobigny France 2nd ERIC workshop on TP53 analysis in CLL, Stresa 2017 TP53 abnormalities :
More informationClinical Overview: MRD in CLL. Dr. Matthias Ritgen UKSH, Medizinische Klinik II, Campus Kiel
Clinical Overview: MRD in CLL Dr. Matthias Ritgen UKSH, Medizinische Klinik II, Campus Kiel m.ritgen@med2.uni-kiel.de Remission in CLL Clinical criteria (NCI->WHO) Lymphadenopathy Splenomegaly Hepatomegaly
More informationXIII. Molecular pathogenesis of transformed lymphomas
Hematological Oncology Hematol Oncol 2015; 33: 70 74 Published online in Wiley Online Library (wileyonlinelibrary.com).2221 Supplement Article XIII. Molecular pathogenesis of transformed lymphomas Davide
More informationCAPP-seq. Davide Rossi, M.D., Ph.D.
CAPP-seq Davide Rossi, M.D., Ph.D. Hematology IOSI - Oncology Institute of Southern Switzerland IOR - Institute of Oncology Research Bellinzona - Switzerland CAPP-seq capture and sequencing approach Exon
More informationAktuelle Therapiestandards und neue Entwicklungen bei der CLL Primärtherapie und Risikostratifikation
Aktuelle Therapiestandards und neue Entwicklungen bei der CLL Primärtherapie und Risikostratifikation Dr. med. Petra Langerbeins Universitätsklinik Köln Deutsche CLL Studiengruppe (DCLLSG) OFFENLEGUNG
More informationRichter s Syndrome: Risk, Predictors and Treatment
Richter s Syndrome: Risk, Predictors and Treatment 10/23/2015 John N. Allan MD Assistant Professor of Medicine Division of Hematology and Medical Oncology CLL Research Center Weill Cornell Medicine Agenda
More informationCLL: disease specific biology and current treatment. Dr. Nathalie Johnson
CLL: disease specific biology and current treatment Dr. Nathalie Johnson Disclosures Consultant and Advisory boards Roche, Abbvie, Gilead, Jansson, Lundbeck,Merck Research funding Roche, Abbvie, Lundbeck
More informationCLL: MRD as a Surrogate Endpoint for Clinical Trials White Oak February 27, Chronic Lymphocytic Leukemia. Paolo Ghia
CLL: MRD as a Surrogate Endpoint for Clinical Trials White Oak February 27, 2013 Chronic Lymphocytic Leukemia Paolo Ghia CLL: MRD as a Surrogate Endpoint for Clinical Trials White Oak February 27, 2013
More informationGeorg Hopfinger 3. Med.Abt and LBI for Leukemiaresearch and Haematology Hanusch Krankenhaus,Vienna, Austria
Chronic lymphocytic Leukemia Georg Hopfinger 3. Med.Abt and LBI for Leukemiaresearch and Haematology Hanusch Krankenhaus,Vienna, Austria georg.hopfinger@wgkk.at CLL Diagnosis and Staging Risk Profile Assessment
More informationMRD Negativity as an Outcome in CLL: Ongoing Challenges with Del 17p Patients
MRD Negativity as an Outcome in CLL: Ongoing Challenges with Del 17p Patients Jennifer R Brown, MD PhD Director, CLL Center Dana-Farber Cancer Institute Associate Professor Harvard Medical School November
More informationBiomarkers in Chronic Lymphocytic Leukemia: the art of synthesis. CLL Immunogenetics. Overview. Anastasia Chatzidimitriou
Biomarkers in Chronic Lymphocytic Leukemia: the art of synthesis CLL Immunogenetics Overview Anastasia Chatzidimitriou Belgrade March 17, 2018 B cells: multiple receptors B cell receptor IG unique signature
More informationInitial Diagnosis and Treatment 81 Male
Case SH2017-0359 Shiraz Fidai 1, Sandeep Gurbuxani 1, Girish Venkataraman 1, Gordana Raca 2, Madina Sukhanova 3, Michelle M Le Beau 3, Y. Lynn Wang 4, Mir Alikhan 4, Megan M.McNerney 4, Yuri Kobzev 4,
More informationMutations in chronic lymphocytic leukemia and how they affect therapy choice: focus on NOTCH1, SF3B1, and TP53
GENETICS OF CHRONIC LYMPHOCYTIC LEUKEMIA AND LYMPHOPLASMACYTIC LYMPHOMA Mutations in chronic lymphocytic leukemia and how they affect therapy choice: focus on NOTCH1, SF3B1, and TP53 Clive S. Zent 1 and
More informationRisikoprofil-gesteuerte, individualisierte Therapiestrategien bei der CLL. Michael Hallek University of Cologne
Risikoprofil-gesteuerte, individualisierte Therapiestrategien bei der CLL Michael Hallek University of Cologne 100 90 80 70 60 Substantial progress in CLL therapy in one decade 50 40 complete remissions
More informationManagement of Chronic Lymphatic Leukemia Beyond conventional therapy
3 rd Young Hematologists Orientation Program SGPGI Lucknow August 18 th -19 th 218 Management of Chronic Lymphatic Leukemia Beyond conventional therapy Prof. Hari Menon. MD DM Department of Hemato-Oncology
More informationL approccio terapeu-co. Maria Rosaria Villa U.O.C. Ematologia P.O. Ascalesi ASLNA1Centro
L approccio terapeu-co Maria Rosaria Villa U.O.C. Ematologia P.O. Ascalesi ASLNA1Centro DISCLOSURE Nome: Maria Rosaria Cognome: Villa Impiego nell industria farmaceu7ca negli ul7mi 5 anni: NO Interssi
More informationCLL Biology and Initial Management. Gordon D. Ginder, MD Director, Massey Cancer Center Lipman Chair in Oncology
CLL Biology and Initial Management Gordon D. Ginder, MD Director, Massey Cancer Center Lipman Chair in Oncology CLL- Epidemiology Most common adult leukemia 25-30% in western world Incidence in US 4.5
More informationHistologic transformation of CLL and other indolent lymphomas
Histologic transformation of CLL and other indolent lymphomas Davide Rossi, M.D., Ph.D. Hematology IOSI - Oncology Institute of Southern Switzerland IOR - Institute of Oncology Reserach Bellinzona - Switzerland
More informationGVHD & GVL in the lymphoma setting: The case of CLL
GVHD & GVL in the lymphoma setting: The case of CLL Peter Dreger Dept. Internal Medicine V University of Heidelberg EBMT: SCT for CLL 2000-2010 Update January 2012 allo auto 400 350 300 250 200 150 100
More informationChronic Lymphocytic Leukemia. Paolo Ghia
Chronic Lymphocytic Leukemia Paolo Ghia Complex Karyotype: a novel predictive marker? Thompson PA et al. Cancer 2015 Complex karyotype superseded del(17p) Anderson MA et al. Blood 2017 Ibrutinib and Idela
More informationASH up-date: Changing the Standard of Care for Patients with. (or: Who to treat with What When?)
ASH up-date: Changing the Standard of Care for Patients with B-cell Chronic Lymphocytic Leukaemia (or: Who to treat with What When?) Dr Anna Schuh, MD, PhD, MRCP, FRCPath Consultant and Senior Lecturer
More informationPrevalence of BTK and PLCγ2 Mutations in Patients relapsing under Ibrutinib. Lydia Scarfò Silvia Bonfiglio Lesley Ann Sutton
Prevalence of BTK and PLCγ2 Mutations in Patients relapsing under Ibrutinib Lydia Scarfò Silvia Bonfiglio Lesley Ann Sutton Patients relapsing on ibrutinib are the new unmet clinical need Woyach J et al.
More informationUpdate: Chronic Lymphocytic Leukemia
ASH 2008 Update: Chronic Lymphocytic Leukemia Improving Patient Response to Treatment with the Addition of Rituximab to Fludarabine-Cyclophosphamide ASH 2008: Update on chronic lymphocytic leukemia CLL-8
More informationChronic Lymphocytic Leukemia: Prognostic Factors, Supportive Care Issues and Therapeutic Advances
Chronic Lymphocytic Leukemia: Prognostic Factors, Supportive Care Issues and Therapeutic Advances 2017 Master Class Course John C. Byrd, MD D Warren Brown Chair of Leukemia Research Distinguished University
More informationRaising the Bar in CLL Michael E. Williams, MD, ScM Byrd S. Leavell Professor of Medicine Chief, Hematology/Oncology Division
Raising the Bar in CLL Michael E. Williams, MD, ScM Byrd S. Leavell Professor of Medicine Chief, Hematology/Oncology Division University of Virginia Cancer Center The Clinical Continuum of CLL Early asymptomatic
More informationTargeting Bruton s Tyrosine Kinase (BTK)
Targeting Bruton s Tyrosine Kinase (BTK) Lapo Alinari, MD, PhD 4 th International Conference, Translational Research in Oncology Forli, November 9-11/2016 The Ohio State University Comprehensive Cancer
More informationTreatment Landscape in R/R DLBCL Novel Targets and Strategies. Wyndham H. Wilson, M.D., Ph.D. Senior Investigator
Treatment Landscape in R/R DLBCL Novel Targets and Strategies Wyndham H. Wilson, M.D., Ph.D. Senior Investigator Gene-expression profiling of DLBCL subtypes Roschewski, M. et al. (2013) Nat. Rev. Clin.
More informationThe mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment
INDIVIDUALIZING THERAPY IN CHRONIC LYMPHOCYTIC LEUKEMIA The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment Gianluca Gaidano 1 and Davide Rossi 2,3 1 Division
More informationBENDAMUSTINE + RITUXIMAB IN CLL
BENDAMUSTINE + RITUXIMAB IN CLL Barbara Eichhorst Bologna 13. November 2017 CONFLICT OF INTERESTS 1. Advisory Boards Janssen, Gilead, Roche, Abbvie, GSK 2. Honoraria Roche, GSK, Gilead, Janssen, Abbvie,
More informationWhat can a «solid-tumour» expert learn from lymphomas and myeloma management
What can a «solid-tumour» expert learn from lymphomas and myeloma management Franco Cavalli M.D., F.R.C.P. Scientific Director Oncology Institute of Southern Switzerland (IOSI) A bit of history (I) CT
More informationLEUCEMIA LINFATICA CRONICA: TERAPIA DEL PAZIENTE IN RECIDIVA
CORSO TEORICO-PRATICO PER LA GESTIONE OTTIMALE DEI PAZIENTI AFFETTI DA LINFOMA MANTELLARE, LINFOMA FOLLICOLARE E LEUCEMIA LINFATICA CRONICA Torino, 21-23 Maggio 2018 LEUCEMIA LINFATICA CRONICA: TERAPIA
More informationUpdate on Management of CLL. Presenter Disclosure Information. Chronic Lymphocytic Leukemia. Audience Response Question?
Welcome to Master Class for Oncologists New York, NY May 14, 2010 Session 5: 4:20 PM - 5:00 PM Update on Management of CLL John C. Byrd, MD D Warren Brown Professor of Leukemia Research Professor of Medicine
More information15 th Annual Miami Cancer Meeting
15 th Annual Miami Cancer Meeting CLL and CML Mohamed A. Kharfan-Dabaja, MD, MBA, FACP Director, Blood and Marrow Transplantation and Cellular Therapies Mayo Clinic Jacksonville, FL 15 th Annual Miami
More informationHeng Li, Wenjie Xiong, Huimin Liu, Shuhua Yi, Zhen Yu, Wei Liu, Rui Lyu, Tingyu Wang, Dehui Zou, Zengjun Li, Lugui Qiu
Original Article Serum LDH level may predict outcome of chronic lymphocytic leukemia patients with a 17p deletion: a retrospective analysis of prognostic factors in China Heng Li, Wenjie Xiong, Huimin
More informationAddition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial
Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial Hallek M et al. Lancet 2010;376:1164-74. Introduction > In patients with CLL, the
More informationMolecular Markers to Guide Therapy - Chronic Lymphocytic Leukaemia - Stephan Stilgenbauer Ulm University
Molecular Markers to Guide Therapy - Chronic Lymphocytic Leukaemia - Stephan Stilgenbauer Ulm University Chronic Lymphocytic Leukaemia (CLL) Most common leukaemia in adults Diagnosis straightforward CD19+/CD5+/CD23+
More informationAdvances in the treatment of Chronic Lymphocytic Leukemia
Advances in the treatment of Chronic Lymphocytic Leukemia Lab of B Cell Neoplasia - Division of Experimental Oncology Strategic Research Program on CLL Department of Onco-Hematology Università Vita-Salute
More informationallosct and CLL in the BCRi era time for a study
allosct and CLL in the BCRi era time for a study Patient characteristics in BCRi studies and allosct candidates DIFFER Facts on BCRi no Cure Risk factors for shorter BCRi efficacy in MV analysis? PA-refractory
More informationMolecular Pathology Evaluation Panel and Molecular Pathology Consortium Advice Note
Molecular Pathology Evaluation Panel and Molecular Pathology Consortium Advice Note MPEP/MPC Advice Note 2016-02 June 2016 Test evaluated: Tumour Protein p53 (TP53) Molecular Pathology Evaluation Panel
More informationImproving Response to Treatment in CLL with the Addition of Rituximab and Alemtuzumab to Chemoimmunotherapy
New Evidence reports on presentations given at ASH 2009 Improving Response to Treatment in CLL with the Addition of Rituximab and Alemtuzumab to Chemoimmunotherapy From ASH 2009: Chronic Lymphocytic Leukemia
More informationManagement of CLL in the Targeted Therapy Era
Management of CLL in the Targeted Therapy Era Jennifer A. Woyach, MD The Ohio State University The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove
More informationChronic Lymphocytic Leukemia - BIOLOGY
Chronic Lymphocytic Leukemia - BIOLOGY Paolo Ghia Lab of B Cell Neoplasia - Division of Molecular Oncology Lymphoma Unit Department of Onco-Hematology Università Vita-Salute San Raffaele - Milano Istituto
More informationState of the Art Treatment for Relapsed Mantle Cell Lymphoma
Winship Cancer Institute of Emory University State of the Art Treatment for Relapsed Mantle Cell Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor, BMT Program Emory University- Winship Cancer Institute
More informationSequencing of chronic lymphocytic leukemia therapies
CHRONIC LYMPHOCYTIC LEUKEMIA Sequencing of chronic lymphocytic leukemia therapies Jacqueline C. Barrientos CLL Research and Treatment Program, Department of Internal Medicine, Hofstra Northwell School
More informationMED B Form CLL. Johannes Schetelig. London 09/April/
www.ebmt.org MED B Form CLL Johannes Schetelig London 09/April/2013 Content Update on CLL (15 ) Experiment with mini MED B CLL Assessment of pre-treatment in CLL Cytogenetics in CLL What is the IGVH-Gene
More informationNGS IMMUNOGENETICS IN CLL RESEARCH. Andreas Agathangelidis Post-doc researcher Institute of Applied Biosciences, CERTH
NGS IMMUNOGENETICS IN CLL RESEARCH Andreas Agathangelidis Post-doc researcher Institute of Applied Biosciences, CERTH ERIC & Euroclonality-NGS workshop Rotterdam, 24 November 2017 1. NGS Immunoprofiling
More informationUNMET NEEDS OF PATIENTS WITH CLL/SLL AND FL. June 6, 2018
UNMET NEEDS OF PATIENTS WITH CLL/SLL AND FL June 6, 2018 0 PRESENTATION OVERVIEW IN CLL/SLL AND FL: Review patient heterogeneity and its connection to unmet needs Explore unmet needs within the CLL/SLL
More informationCLL: future therapies. Dr. Nathalie Johnson
CLL: future therapies Dr. Nathalie Johnson Disclosures Consultant and Advisory boards Roche, Abbvie, Gilead, Jansson, Lundbeck,Merck Research funding Roche, Abbvie, Lundbeck Outline Treatment of relapsed
More informationSupplemental data. EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic. leukemia
Supplemental data EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia Emma Young 1*, Daniel Noerenberg 2*, Larry Mansouri 1, Viktor Ljungström 1, Mareike Frick 2,
More informationMantle Cell Lymphoma. A schizophrenic disease
23 maggio, 2018 Mantle Cell Lymphoma A schizophrenic disease Patients relapsed after Auto transplant EBMT registry 2000-2009 (n=360) 19 months OS 24 months OS Dietrich S, Ann Oncol 2014 Patients receiving
More informationBackground. Approved by FDA and EMEA for CLL and allows for treatment without chemotherapy in all lines of therapy
Updated Efficacy and Safety From the Phase 3 RESONATE-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Abstract
More informationCLL Brad Kahl, MD Professor of Medicine
CLL 2016 Brad Kahl, MD Professor of Medicine Disclosures Advisory Committee Consulting Agreements Contracted Research Roche Laboratories Inc, Takeda Oncology Bristol-Myers Squibb Company, Celgene Corporation,
More informationCLL - venetoclax. Peter Hillmen St James s University Hospital Leeds 10 th May 2016
CLL - venetoclax Peter Hillmen peter.hillmen@nhs.net St James s University Hospital Leeds 10 th May 2016 Pathophysiology of CLL: Proliferation vs Apoptosis Proliferation Apoptosis Ki-67 Expression Bcl-2
More informationTemplate for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Template for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Version: CLLBiomarkers 1.0.0.2 Protocol Posting Date: June 2017
More informationLa terapia della LMC: è possibile guarire senza trapianto? Fabrizio Pane
La terapia della LMC: è possibile guarire senza trapianto? Fabrizio Pane What could be the concept of Cure in CML? Sustained DMR with or without TKI therapy And 100% CML-related survival And QoL comparable
More informationChronic Lymphocytic Leukemia Mantle Cell Lymphoma Elias Campo
Chronic Lymphocytic Leukemia Mantle Cell Lymphoma Elias Campo Hospital Clinic, University of Barcelona Small B-cell lymphomas NAIVE -B LYMPHOCYTE MEMORY CELL CLL MCL FL MZL Small cell size Low proliferation
More informationPatient Selection for allogeneic stem cell transplantation in CLL KOEN VAN BESIEN, MD WEILL CORNELL MEDICAL COLLEGE, NY
Patient Selection for allogeneic stem cell transplantation in CLL KOEN VAN BESIEN, MD WEILL CORNELL MEDICAL COLLEGE, NY Topics CLL Complicated CLL Richter s transformation What did we learn about allotransplant
More informationSF3B1, NOTCH1, MYD88, BIRC3
/, Vol. 6, No.7 Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans Yi Xia 1, Lei Fan 1, Li Wang
More informationIs there a place for allogeneic stem cell transplantation in chronic lymphocytic leukaemia in the era of the new molecules?
185 Is there a place for allogeneic stem cell transplantation in chronic lymphocytic leukaemia in the era of the new molecules? D. Selleslag, MD SUMMARY Allogeneic stem cell transplantation can cure about
More informationThe genetic landscape of high-risk CLL
The genetic landscape of high-risk CLL Jonathan Strefford PhD Reader in Molecular Haematology Cancer Genomics Treatment development 2010 Further development of Small molecules for Stratified CLL treatment
More informationHighlights in chronic lymphocytic leukemia
Congress Highlights CLL Highlights in chronic lymphocytic leukemia A. Janssens, MD, PhD 1 As new data on indolent non-hodgkin lymphoma (inhl) were not that compelling, only highlights on chronic lymphocytic
More informationTranslocations and clonality detection in lymphoproliferative disorders by capturebased Next-generation sequencing
Translocations and clonality detection in lymphoproliferative disorders by capturebased Next-generation sequencing Dörte Wren MSc MPhil on behalf of the EuroClonality-NGS consortium Molecular Diagnostics
More informationCLL: from past to present from present to future
CLL: from past to present from present to future Ann Janssens MD, PhD Hematology UZ Leuven BHS course, 8 th february 2015 1 2 Part1 Diagnosis Prognostic factors Part 2 Complications Treatment B-cell neoplasms
More informationB-cell Chronic Lymphoproliferative Disorders of the Blood and Bone Marrow
B-cell Chronic Lymphoproliferative Disorders of the Blood and Bone Marrow Sanam Loghavi, MD Department of Hematopathology University of Texas MD Anderson Cancer Center Houston, TX Disclosures I have no
More informationDr Claire Burney, Lymphoma Clinical Fellow, Bristol Haematology and Oncology Centre, UK
EMBT LWP 2017-R-05 Research Protocol: Outcomes of patients treated with Ibrutinib post autologous stem cell transplant for mantle cell lymphoma. A retrospective analysis of the LWP-EBMT registry. Principle
More informationManagement of Patients With Relapsed Chronic Lymphocytic Leukemia
Management of Patients With Relapsed Chronic Lymphocytic Leukemia Polina Shindiapina, MD, PhD, and Farrukh T. Awan, MD Abstract The management of chronic lymphocytic leukemia (CLL) has improved significantly
More informationSmall, mature-appearing appearing
B-cell Chronic Lymphoproliferative Disorders of the Blood and Bone Marrow Disclosures I have nothing to disclose. Jeffrey L. Jorgensen, MD, PhD Department of Hematopathology, UT M.D. Anderson Cancer Center,
More informationHighlights of ICML 2015
Highlights of ICML 2015 Jonathan W. Friedberg M.D. Director, James P. Wilmot Cancer Center Statistics, ICML 2015: a global meeting Almost 3700 participants. 90 countries represented. Attendees: USA 465
More informationCHRONIC LYMPHOCYTIC LEUKEMIA
CHRONIC LYMPHOCYTIC LEUKEMIA Effective Date: January, 2017 The recommendations contained in this guideline are a consensus of the Alberta Provincial Hematology Tumour Team synthesis of currently accepted
More informationIdelalisib in the Treatment of Chronic Lymphocytic Leukemia
Idelalisib in the Treatment of Chronic Lymphocytic Leukemia Jacqueline C. Barrientos, MD Assistant Professor of Medicine Hofstra North Shore LIJ School of Medicine North Shore LIJ Cancer Institute CLL
More informationAnna Schuh, MD, Ph.D.
Anna Schuh, MD, Ph.D. Current position: Associate Professor and Director of Molecular Diagnostics in the Department of Oncology University of Oxford Honorary Consultant Hematologist at Oxford University
More informationWelcome & Introductions
Living with Chronic Lymphocytic Leukemia (CLL) Welcome & Introductions Dr. Brander s slides are available for download at www.lls.org/programs Wednesday, July 12, 2017 1 Living with Chronic Lymphocytic
More informationConcomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia
Concomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia Feng-Ming Tien, Hsin-An Hou, Jih-Luh Tang, Yuan-Yeh Kuo, Chien-Yuan Chen, Cheng-Hong Tsai, Ming Yao, Chi-Cheng
More informationOutcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion
ARTICLES Chronic Lymphocytic Leukemia Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion Paolo Strati, Michael J. Keating, Susan M. O Brien, Alessandra Ferrajoli, Jan Burger,
More informationChromosome Banding Analysis in CLL Panagiotis Baliakas, MD-PhD
Chromosome Banding Analysis in CLL Panagiotis Baliakas, MD-PhD Dept of Immunology, Genetics and Pathology Science for Life Laboratory, Uppsala University Medical Genetics, University Hospital, Uppsala
More informationMantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients
Mantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients Olivier Hermine MD, PhD Department of Hematology INSERM and CNRS, Imagine Institute Necker Hospital Paris, France
More informationTHE FUTURE IS PROMISING. Dr. Claire Dearden
THE FUTURE IS PROMISING Dr. Claire Dearden Lymphoma Haematological malignancies are the 5 th commonest cancer Lymphomas represent 50% of blood cancers Crude incidence rate of 20 cases per 100,000 of the
More information